• SCL Science will absorb wholly owned SCL Healthcare, with the merger scheduled for Jan. 1, 2027.
• The transaction aims to consolidate data-driven precision medicine research operations and improve management efficiency.
• No new shares or merger consideration will be issued, leaving share capital and the largest shareholder’s ownership unchanged.
• Consolidated financial effects are expected to be limited because the subsidiary is already consolidated.
• SCL Healthcare’s existing businesses, locations and employees will be retained, with its assets and liabilities transferred to the surviving company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SCL Science Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261029000639), on October 29, 2026, and is solely responsible for the information contained therein.